Analysts think VRNA stock price could increase by 26%
Mar 16, 2025, 11:25 AM
-6.07%
What does VRNA do
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
11 analysts think VRNA stock price will increase by 26.11%. The current median analyst target is $77.52 compared to a current stock price of $61.47. The lowest analysts target is $72.72 and the highest analyst target is $97.65.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
